TARA - Protara Therapeutics GAAP EPS of -$3.46

2023-03-08 09:06:52 ET

• Protara Therapeutics press release ( NASDAQ: TARA ): Q4 GAAP EPS of -$3.46.
• Net loss of $39.0 million, compared with a net loss of $10.2 million for the same period in 2021.
• Net loss in the fourth quarter of 2022 included a non-cash goodwill impairment charge of $29.5 million associated with the accounting for the reverse merger transaction in January of 2020.
• As of December 31, 2022, cash, cash equivalents and marketable debt securities totaled $102.3 million.
• The Company expects its cash, cash equivalents, and marketable debt securities will be sufficient to fund its planned operations and data milestones into 2025.

For further details see: